As an easily obtainable plasma biomarker, hs-cTnT may be of use in the incremental risk stratification of patients with T2D into high- and low-risk subgroups and to translate prognostic projections into individualized management plans to address the excess heart failure risk in diabetes. This evidence concerns the gene TNNT2 and type 2 diabetes mellitus.